Hims & Hers Health Jumps 41.7% After Novo Nordisk GLP-1 Drug Partnership
Shares of telehealth firm Hims & Hers Health jumped 41.7% after it partnered with Novo Nordisk to offer FDA-approved GLP-1 weight-loss drugs Ozempic and Wegovy on its platform and halted sales of its compounded semaglutide. The collaboration resolved a pending lawsuit as Novo Nordisk dismissed legal action against the company.
1. Collaboration Details
Hims & Hers Health secured distribution rights for Novo Nordisk’s FDA-approved GLP-1 drugs Ozempic and Wegovy, integrating them into its telehealth platform. The company agreed to cease marketing and sales of compounded semaglutide products, positioning itself to offer only approved medications.
2. Legal Settlement and Market Reaction
Novo Nordisk withdrew its lawsuit over compounded drug sales, ending the legal dispute and clearing a major obstacle for Hims & Hers Health. Following the announcement, shares surged 41.7%, reflecting investor optimism about the company’s shift toward established pharmaceutical partnerships and improved regulatory compliance.